<DOC>
	<DOCNO>NCT02894385</DOCNO>
	<brief_summary>Evaluate potential effect hepatic renal impairment pharmacokinetics , safety tolerability BAY 1841788 ( ODM-201 ) .</brief_summary>
	<brief_title>Effect Hepatic Renal Impairment Pharmacokinetics , Safety Tolerability BAY1841788 ( ODM-201 )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>All subject Male white subject 45 79 year age body mass index 18 34 kg/m*2 ( inclusive ) . Patients moderate hepatic impairment ( Part 1 ) Patients document liver cirrhosis confirm histopathology , e.g. , previous liver biopsy , laparoscopy , ultrasound , fibroscan moderate hepatic impairment ( define Child Pugh class B ) . Patients severe renal impairment ( Part 1 ) Patients severe renal impairment estimate glomerular filtration rate 1529 mL/min/1.73 m*2 , dialysis expect start dialysis next 3 month ( Stage 4 ) . Healthy subject Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring estimate glomerular filtration rate &gt; 90 mL/min ( accord Modified Diet Renal Disease equation ) . Patients moderate renal impairment ( Part 2 ) Patients moderate renal impairment estimate glomerular filtration rate 3059 mL/min/1.73 m*2 ( Stage 3 ) . Patients mild renal impairment ( Part 2 ) Patients mild renal impairment estimate glomerular filtration rate ( eGFR ) 6079 mL/min/1.73 m*2 ( Stage 2 ) . Patients mild hepatic impairment ( Part 2 ) Patients document liver cirrhosis confirm histopathology , e.g. , previous liver biopsy , laparoscopy , ultrasound , fibroscan . Patients mild hepatic impairment ( define Child Pugh class A ) . Severe cerebrovascular cardiac disorder , e.g. , myocardial infarction le 6 month prior dose , congestive heart failure New York Heart Association ( NYHA ) grade III IV . Subjects percutaneous transluminal coronary angioplasty coronary artery bypass graft le 6 month prior study drug administration . Strong cytochrome P450 ( CYP ) 3A4 inhibitor strong CYP3A4 inducer within 28 day 5 drug halflives ( drug halflife patient know ) , start study treatment . Known BCRP ( breast cancer resistant protein ) OATP ( organic aniontransporting polypeptide ) substrates specifically mention protocol within 28 day 5 drug halflives ( drug halflife patient know ) , start study treatment . Smoking 20 cigarette daily .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>